Back to search

Peptide record

TPDB10058

Antibacterial Anticancer Toxicity standard
22 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB10058
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia
standard
No
A 22-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from AntiBP3 and Peptipedia, with an available 3D structural model.
Sequence
WFGKLYRGKTKVVKKVKGLLKG
Physicochemical Analysis
C122H205N33O25
ANDCEQHIMPS
K
2534.18
11.28
8
0
9
+8
2.53
-0.432
92.73
Mammalian: 2.8 hour Yeast: 3 min E.coli: 2 min
6990
275.83
2
Residue Composition
number
0
A
1
R
0
N
0
D
0
C
0
E
0
Q
4
G
0
H
0
I
3
L
7
K
0
M
1
F
0
P
0
S
1
T
1
W
1
Y
3
V
Amino Acid Distribution
A: 0 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 4 H: 0 I: 0 L: 3 K: 7 M: 0 F: 1 P: 0 S: 0 T: 1 W: 1 Y: 1 V: 3
Chemical Descriptors
22
C122H205N33O25
2534.18
11.28
+8
2.53
-0.432
Evidence Records 11 records
Evidence 1 Activity

Activity

MIC
Antibacterial
12.5-25 µg/mL

Target

Klebsiella pneumoniae KPC

Source & Reference

NA

Other

active against K. pneumoniae KPC (MIC 12.5-25 ug/ml), ESBL E. coli (MIC 6.25 ug/ml), XDR A. baumannii (MIC 3.1-6.25 ug/ml), MDR P. aeruginosa
Evidence 2 Activity

Activity

MIC
Antibacterial
6.25 µg/mL

Target

Escherichia coli

Source & Reference

NA

Other

active against K. pneumoniae KPC (MIC 12.5-25 ug/ml), ESBL E. coli (MIC 6.25 ug/ml), XDR A. baumannii (MIC 3.1-6.25 ug/ml), MDR P. aeruginosa (MIC 12.5 ug/ml), S. aureus MRS
Evidence 3 Activity

Activity

MIC
Antibacterial
3.1-6.25 µg/mL

Target

A. baumannii

Source & Reference

NA

Other

active against K. pneumoniae KPC (MIC 12.5-25 ug/ml), ESBL E. coli (MIC 6.25 ug/ml), XDR A. baumannii (MIC 3.1-6.25 ug/ml), MDR P. aeruginosa (MIC 12.5 ug/ml), S. aureus MRSA (MIC25-50 ug/ml), S. epidermidis (MIC
Evidence 4 Activity

Activity

MIC
Antibacterial
12.5 µg/mL

Target

Pseudomonas aeruginosa

Source & Reference

NA

Other

12.5-25 ug/ml), ESBL E. coli (MIC 6.25 ug/ml), XDR A. baumannii (MIC 3.1-6.25 ug/ml), MDR P. aeruginosa (MIC 12.5 ug/ml), S. aureus MRSA (MIC25-50 ug/ml), S. epidermidis (MIC 25 ug/ml), and E. faecalis anti-VRE
Evidence 5 Activity

Activity

MIC
Antibacterial
25-50 µg/mL

Target

Staphylococcus aureus MRSA

Source & Reference

NA

Other

C 6.25 ug/ml), XDR A. baumannii (MIC 3.1-6.25 ug/ml), MDR P. aeruginosa (MIC 12.5 ug/ml), S. aureus MRSA (MIC25-50 ug/ml), S. epidermidis (MIC 25 ug/ml), and E. faecalis anti-VRE (MIC 25-50 ug/ml). In total, 70
Evidence 6 Activity

Activity

MIC
Antibacterial
25 µg/mL

Target

Staphylococcus epidermidis

Source & Reference

NA

Other

MIC 3.1-6.25 ug/ml), MDR P. aeruginosa (MIC 12.5 ug/ml), S. aureus MRSA (MIC25-50 ug/ml), S. epidermidis (MIC 25 ug/ml), and E. faecalis anti-VRE (MIC 25-50 ug/ml). In total, 70 clinical strains were tested an
Evidence 7 Activity

Activity

MIC
Antibacterial
25-50 µg/mL

Target

Enterococcus faecalis anti-VRE

Source & Reference

NA

Other

osa (MIC 12.5 ug/ml), S. aureus MRSA (MIC25-50 ug/ml), S. epidermidis (MIC 25 ug/ml), and E. faecalis anti-VRE (MIC 25-50 ug/ml). In total, 70 clinical strains were tested and the results are expressed as a range.
Evidence 8 Activity

Activity

5% Hemolysis
Toxicity
3 µM
Hemolytic Cytotoxic
5% Hemolysis | 3 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Fish-derived antimicrobial peptides: Activity of a chionodracine mutant against bacterial models and human bacterial pathogens. | Dev Comp Immunol | 2019
Evidence 9 Activity

Activity

30% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
30% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Fish-derived antimicrobial peptides: Activity of a chionodracine mutant against bacterial models and human bacterial pathogens. | Dev Comp Immunol | 2019
Evidence 10 Activity

Activity

3.84% Killing
Toxicity
64 µM
Cytotoxic
3.84% Killing | 64 | µM | target cell: Human umbilical vein endothelial cells HUVEC

Target

Human umbilical vein endothelial cells HUVEC

Source & Reference

NA
DBAASP
Fish-derived antimicrobial peptides: Activity of a chionodracine mutant against bacterial models and human bacterial pathogens. | Dev Comp Immunol | 2019
Evidence 11 Activity

Activity

% Hemolysis
Toxicity
5 %
Hemolytic Cytotoxic
Hemolytic_activity: Human erythrocytes: 5% Hemolysis=3µM 30% Hemolysis=50µM | Cytotoxicity: HUVEC: 3.84% Killing=64 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
Dev Comp Immunol. 2019 Jul 96:9-17.